RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · SPECIFICATIONS AND PRICES REQUIRE FINAL CONFIRMATION

PEPTIDES BIO / MATERIAL RECORD

SS-31 10mg

Technical record, pack format and document request for qualified research review.

RESEARCH USE ONLYRUO

SS-31 10mg

Purity / identity≥99% purity
Molecular weight639.79 g/mol
Pack size10mg

Volume pricing

Configured totals update at each quantity threshold.

Configured total$70.29
SKU: ps-ss-31-10mg

Research record

Pending manual confirmation

Research overview

SS‑31, officially known as Elamipretide or MTP‑131, is a synthetic tetrapeptide composed of four amino acids. Unlike conventional free‑radical scavengers, SS‑31 is a mitochondria‑targeted peptide that selectively accumulates in the inner mitochondrial membrane. Its primary molecular target is cardiolipin—a phospholipid found almost exclusively in the inner mitochondrial membrane. By specifically binding to cardiolipin, SS‑31 stabilizes mitochondrial cristae architecture, preserves the integrity of the respiratory chain, reduces mitochondrial reactive oxygen species (ROS) production, and enhances ATP synthesis. In contrast to ordinary antioxidants that directly scavenge free radicals, SS‑31 attenuates oxidative damage at its source by repairing the mitochondrial membrane structure.

Research reference

Product FAQ

What is SS-31?

A mitochondria‑targeting tetrapeptide (also known as Elamipretide, MTP‑131, Bendavia) that stabilizes mitochondrial structure by binding to cardiolipin on the inner mitochondrial membrane, reducing ROS production and enhancing ATP synthesis.

What is the mechanism of action of SS‑31?

SS‑31 selectively accumulates in the inner mitochondrial membrane, binds to cardiolipin, stabilizes cristae structure, inhibits cytochrome c peroxidase activity, and reduces oxidative damage. It also inhibits mitochondrial permeability transition pore opening, increases ATP synthesis, and exhibits anti‑inflammatory effects.

Is there clinical research supporting SS‑31?

Yes. In 2025, SS‑31 received FDA accelerated approval for Barth syndrome, a rare mitochondrial disease. It is also in clinical trials for multiple indications including heart failure, kidney injury, and ophthalmic diseases.

How does SS‑31 differ from common antioxidants?

Traditional antioxidants like Coenzyme Q10 and MitoQ do not specifically target mitochondrial membrane components. SS‑31 precisely targets the inner mitochondrial membrane by binding to cardiolipin, achieving 1000‑5000‑fold accumulation in mitochondria with high specificity.

What are the main research areas for SS‑31?

Research covers a wide range of areas, including:

· Neurodegenerative diseases (Parkinson's, Alzheimer's, etc.)

· Cardiovascular diseases (myocardial infarction, ischemia‑reperfusion injury, heart failure)

· Aging and age‑related diseases (muscle aging, osteoarthritis)

· Kidney diseases (acute kidney injury)

· Ophthalmic diseases (glaucoma)

· Female reproductive aging (improving aged oocyte quality)

· Barth syndrome (FDA accelerated approval granted)

Data sheet

Manual confirmation
Material Type
Single material
Purity Identity
≥99% purity
Molecular Weight
639.79 g/mol
Pack Size
10mg
Molecular Formula
C32H49N9O5
CAS Number
736992-21-5
Amino Acid Sequence
H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2
PubChem CID
11764719
Storage conditions overview
Storage typeLong-termTemperature-80°CDuration2-3 yearsNotesSealed, dark, minimal opening
Storage typeStandardTemperature-20°CDuration1-2 yearsNotesSealed, dark, moisture-proof
Storage typeShort-termTemperature4°CDuration1-2 weeksNotesTemporary storage, use promptly
Storage typeWorking SolutionTemperature4°CDuration1-7 daysNotesReconstituted, short-term, avoid freeze-thaw

Related research guides

Review before you request.